Navigation Links
Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Date:12/9/2010

EAST HANOVER, N.J., Dec. 9, 2010 /PRNewswire/ -- A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas(1).  

Findings from a randomized, Phase II study of 111 patients showed the proportion of metastatic breast cancer patients without tumor progression at six months was 61.1% for those taking everolimus plus tamoxifen (95% confidence interval [CI], 46.9 to 74.1) versus 42.1% for patients treated with tamoxifen alone (95% CI, 29.1 to 55.9); p=0.045(1).  

Disease progression was delayed by a median of 8.6 months in patients treated with the combination versus 4.5 months in patients treated with tamoxifen alone, with everolimus in combination with tamoxifen providing a statistically significant reduction in the risk of disease progression by 47% (hazard ratio=0.53 [95% CI, 0.35 to 0.81]; log-rank test: p=0.0026, exploratory analysis). Side effects were generally manageable in both study arms. As of October 2010, there were 25 patient deaths in the tamoxifen arm versus nine in the everolimus plus tamoxifen arm (hazard ratio=0.32 [95% CI, 0.15 to 0.68]; log-rank test: p=0.0019)(1).

This Phase II trial is conducted by the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (the French GINECO Group).

Everolimus is an investigational agent for the treatment of patients with breast cancer. Everolimus targets mTOR in cancer cells, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(7,8).

"The almost doubling of time to di
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... and ,S-HERTOGENBOSCH, the Netherlands ... http://www.healthlinkeurope.com ) has expanded its North American operations through ... facility, providing warehousing, fulfillment and order to cash services ... , utilizing our global ERP platform. ... serving our customers in Europe ...
(Date:9/2/2014)... Sept. 2, 2014  PANTHERx Specialty Pharmacy announced ... Accreditation from URAC, a Washington, DC ... quality standards for the health care industry. ... The URAC accreditation process demonstrates a commitment ... to improve business processes through benchmarking organizations against ...
(Date:9/2/2014)... 2, 2014  Cyberonics, Inc. (NASDAQ: ... clinical study.  Results of the study presented by ... European cardiology congress and concurrently published by the ... Regulation Therapy (ART) in patients with moderate to ... is safe, improves the heart,s ability to pump ...
Breaking Medicine Technology:HealthLink Europe opens North American medical warehouse operation 2PANTHERx Specialty Pharmacy Applying for URAC Specialty Pharmacy Accreditation 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5
(Date:9/2/2014)... The performance of the Lotteries ... five years. Industry revenue is estimated to grow at ... years through 2014-15, following stabilised growth over the past ... from alternate forms of gambling. Horse and sports betting, ... have all become increasingly popular over the past five ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The American ... of a Free-Tuition Guarantee for its ICD-10 Medical Coding ... bring the highest level of confidence to students who ... medical coder, but are faced with the uncertainty brought ... implementation of ICD-10 until October 1st, 2015. , AHDPG’s ...
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, ... birth weight are at risk later in life of having ... risk for heart disease, according to a pair of new ... lifetime disadvantages, researchers in both studies -- published online Sept. ... can be overcome. Education appeared to negate the potential ...
(Date:9/2/2014)... 02, 2014 The Jerry Segal Classic ... on September 19 at The ACE Club and Green ... past 25 years, the Classic, organized by the Friends ... for programs and services designed to support patients and ... , “The Segal Classic is a labor of ...
(Date:9/2/2014)... Washington, New York (PRWEB) September 02, 2014 ... LLP announces that Class Counsel has filed ... for service awards in the class action litigation ... Parker Waichman LLP, the Court-Appointed Class Counsel in ... Heimann & Bernstein, LLP; Audet & Partners, LLP; ...
Breaking Medicine News(10 mins):Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3
... 15, 2007, Philadelphia, PA Researchers found that mesalamine ... with a decrease in incidence of colorectal cancer when ... at the 72nd Annual Scientific Meeting of the American ... Detroit matched 16 patients with ulcerative colitis and Crohns ...
... 2007 Post-hoc and other analyses of secondary endpoints ... plc,s (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis ... in patients with mild to moderate ulcerative colitis. These ... open-label 12-14 month extension study, are being presented this ...
... toothbrush may be the,ultimate plaque fighting tool, but it ... Sonicare and GfK Roper reveals that more than half,(54 ... fell on,the bathroom floor, despite voting the bathroom as ... percent). In addition, nine percent of men,admitted to reusing ...
... Strengthen Strategic Consulting ... Canada, MOUNTAIN VIEW, Calif., Oct. 15 ... of software,strategic consulting, and regulatory services for optimizing ... scientific consulting,services practices with three new hires. Pharsight ...
... total sleep times, both habitually and on the morning after ... higher than objectively measured sleep times, according to a study ... Clinical Sleep Medicine (JCSM). , Graciela E. Silva, PhD, of ... were 40 years of age or older. The participants ...
... October 15 Sanofi Pasteur, the,vaccines division ... Institut Pasteur to develop a vaccine against ... have access to antigens,identified by Institut Pasteur ... the most deadly malaria infections. Sanofi Pasteur,intends ...
Cached Medicine News:Health News:Mesalamine linked to cancer protection for high risk inflammatory bowel disease patients 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 3Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 4Health News:New Survey Uncovers Dirty Little Secrets About America's Oral Care Habits 2Health News:New Survey Uncovers Dirty Little Secrets About America's Oral Care Habits 3Health News:Pharsight Expands Global Consulting Services Teams 2Health News:Pharsight Expands Global Consulting Services Teams 3Health News:People overestimate their self-reported sleep times compared to measures by a sleep test 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 3
... The dual lumen ... a 1.2 mm inner ... ,Dual oval lumen catheters ... while maintaining maximum catheter ...
The mid-sized titanium port is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 1.0 mm....
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
... Used for vascular access. ... facilitates single wall puncture with ... sideport is visualized while maintaining ... Sideport exits the hub of ...
Medicine Products: